These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27567833)

  • 21. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients.
    Figurski MJ; Waligórska T; Toledo J; Vanderstichele H; Korecka M; Lee VM; Trojanowski JQ; Shaw LM;
    Alzheimers Dement; 2012 Jul; 8(4):250-60. PubMed ID: 22748936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study.
    Peters KE; Davis WA; Taddei K; Martins RN; Masters CL; Davis TM; Bruce DG
    J Alzheimers Dis; 2017; 56(3):1127-1133. PubMed ID: 28106562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of plasma β-amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease.
    Wang D; Dai Y; Wang X; Yu P; Qu S; Liu Z; Cao Y; Zhang L; Ping Y; Liu W; Tao Z
    Mikrochim Acta; 2021 Jan; 188(1):24. PubMed ID: 33404755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease.
    Thijssen EH; Verberk IMW; Vanbrabant J; Koelewijn A; Heijst H; Scheltens P; van der Flier W; Vanderstichele H; Stoops E; Teunissen CE
    Sci Rep; 2021 May; 11(1):9736. PubMed ID: 33958661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical Histories of Control Subjects Influence the Biomarker Potential of Plasma Aβ in Alzheimer's Disease: a Meta-analysis.
    Zhang S; Huang SY; An XB; Zeng L; Ai J
    J Mol Neurosci; 2020 Jun; 70(6):861-870. PubMed ID: 32125624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease.
    Lövheim H; Elgh F; Johansson A; Zetterberg H; Blennow K; Hallmans G; Eriksson S
    Alzheimers Dement; 2017 Jul; 13(7):778-782. PubMed ID: 28073031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems.
    Jensen M; Hartmann T; Engvall B; Wang R; Uljon SN; Sennvik K; Näslund J; Muehlhauser F; Nordstedt C; Beyreuther K; Lannfelt L
    Mol Med; 2000 Apr; 6(4):291-302. PubMed ID: 10949910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
    Basun H; Nilsberth C; Eckman C; Lannfelt L; Younkin S
    Dement Geriatr Cogn Disord; 2002; 14(3):156-60. PubMed ID: 12218259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of Rabbit Monoclonal Antibody to Amyloid-β38 (Aβ38): Increased Plasma Aβ38 Levels in Down Syndrome.
    Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Miller DL
    J Alzheimers Dis; 2015; 46(4):1021-32. PubMed ID: 26402629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease by the Plasma and Serum Amyloid-beta 42 Assay through Highly Sensitive Peptoid Nanosheet Sensor.
    Gao H; Liu M; Zhao Z; Yang C; Zhu L; Cai Y; Yang Y; Hu Z
    ACS Appl Mater Interfaces; 2020 Feb; 12(8):9693-9700. PubMed ID: 32013375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of serum β-amyloid peptides, α2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer's disease.
    Wang D; Di X; Fu L; Li Y; Han X; Wu H; Cai L; Meng X; Jiang C; Kong W; Su W
    Neuroreport; 2016 Oct; 27(15):1114-9. PubMed ID: 27541273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.
    Wang T; Xiao S; Liu Y; Lin Z; Su N; Li X; Li G; Zhang M; Fang Y
    Int J Geriatr Psychiatry; 2014 Jul; 29(7):713-9. PubMed ID: 24318929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy.
    Yamashita K; Miura M; Watanabe S; Ishiki K; Arimatsu Y; Kawahira J; Kubo T; Sasaki K; Arai T; Hagino K; Irino Y; Nagai K; Verbel D; Koyama A; Dhadda S; Niiro H; Iwanaga S; Sato T; Yoshida T; Iwata A
    Alzheimers Res Ther; 2022 Jun; 14(1):86. PubMed ID: 35739591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevation of Plasma Amyloid-β Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study.
    Wang J; Qiao F; Shang S; Li P; Chen C; Dang L; Jiang Y; Huo K; Deng M; Wang J; Qu Q
    J Alzheimers Dis; 2018; 64(1):61-69. PubMed ID: 29865072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aβ1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease.
    Pérez-Grijalba V; Pesini P; Allué JA; Sarasa L; Montañés M; Lacosta AM; Casabona D; San-José I; Boada M; Tárraga L; Ruiz A; Sarasa M
    J Alzheimers Dis; 2015; 43(1):47-56. PubMed ID: 25061046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma amyloid beta levels and platelet mitochondrial respiration in patients with Alzheimer's disease.
    Fišar Z; Jirák R; Zvěřová M; Setnička V; Habartová L; Hroudová J; Vaníčková Z; Raboch J
    Clin Biochem; 2019 Oct; 72():71-80. PubMed ID: 30954436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
    Krishnan S; Rani P
    Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay.
    Zhang L; Du X; Su Y; Niu S; Li Y; Liang X; Luo H
    J Nanobiotechnology; 2021 Nov; 19(1):366. PubMed ID: 34789291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.